Tags

Type your tag names separated by a space and hit enter

Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Psychiatry Clin Neurosci. 2007 Feb; 61(1):54-8.PC

Abstract

Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia. The aim of the present study was to investigate glucose and lipid metabolism, and feeding-control parameters in schizophrenia patients treated with long-term risperidone monotherapy. Fifteen patients with paranoid-type schizophrenia who had been treated with risperidone and had Global Assessment of Function (GAF) scores >70 were selected and compared with healthy volunteers (n = 25). Single assessments of psychotic symptoms, side-effects, Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) score, bodyweight, body fat percentage and blood sampling were performed. Fasting blood glucose, insulin, hemoglobin A1c, homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol, triglyceride, high density lipoprotein (HDL)-, low density lipoprotein-cholesterol, adiponectin, prolactin and feeding-control parameters (ghrelin and leptin) were analyzed. The body fat percentage (P = 0.0018), body mass index (BMI) (P = 0.0150), fasting blood glucose (P = 0.0358), triglyceride (P = 0.0377), leptin (P = 0.0243), total ghrelin (P = 0.0067), active ghrelin (P = 0.0241) and prolactin (P < 0.0001) levels of patients treated with risperidone were significantly higher than those of healthy volunteers, while the HDL-cholesterol level (P = 0.0222) was significantly lower. Although the patients had very mild psychiatric symptoms and maintained functionally high levels, the glucose and lipid parameters were significantly impaired compared to healthy volunteers. A high level of plasma ghrelin might increase appetite, leading to exacerbation of metabolic impairment.

Authors+Show Affiliations

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan. tm-mura@jb3.so-net.ne.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17239039

Citation

Murashita, Mari, et al. "Glucose and Lipid Metabolism of Long-term Risperidone Monotherapy in Patients With Schizophrenia." Psychiatry and Clinical Neurosciences, vol. 61, no. 1, 2007, pp. 54-8.
Murashita M, Inoue T, Kusumi I, et al. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neurosci. 2007;61(1):54-8.
Murashita, M., Inoue, T., Kusumi, I., Nakagawa, S., Itoh, K., Tanaka, T., Izumi, T., Hosoda, H., Kangawa, K., & Koyama, T. (2007). Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and Clinical Neurosciences, 61(1), 54-8.
Murashita M, et al. Glucose and Lipid Metabolism of Long-term Risperidone Monotherapy in Patients With Schizophrenia. Psychiatry Clin Neurosci. 2007;61(1):54-8. PubMed PMID: 17239039.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. AU - Murashita,Mari, AU - Inoue,Takeshi, AU - Kusumi,Ichiro, AU - Nakagawa,Shin, AU - Itoh,Kouichi, AU - Tanaka,Teruaki, AU - Izumi,Takeshi, AU - Hosoda,Hiroshi, AU - Kangawa,Kenji, AU - Koyama,Tsukasa, PY - 2007/1/24/pubmed PY - 2007/3/8/medline PY - 2007/1/24/entrez SP - 54 EP - 8 JF - Psychiatry and clinical neurosciences JO - Psychiatry Clin Neurosci VL - 61 IS - 1 N2 - Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia. The aim of the present study was to investigate glucose and lipid metabolism, and feeding-control parameters in schizophrenia patients treated with long-term risperidone monotherapy. Fifteen patients with paranoid-type schizophrenia who had been treated with risperidone and had Global Assessment of Function (GAF) scores >70 were selected and compared with healthy volunteers (n = 25). Single assessments of psychotic symptoms, side-effects, Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) score, bodyweight, body fat percentage and blood sampling were performed. Fasting blood glucose, insulin, hemoglobin A1c, homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol, triglyceride, high density lipoprotein (HDL)-, low density lipoprotein-cholesterol, adiponectin, prolactin and feeding-control parameters (ghrelin and leptin) were analyzed. The body fat percentage (P = 0.0018), body mass index (BMI) (P = 0.0150), fasting blood glucose (P = 0.0358), triglyceride (P = 0.0377), leptin (P = 0.0243), total ghrelin (P = 0.0067), active ghrelin (P = 0.0241) and prolactin (P < 0.0001) levels of patients treated with risperidone were significantly higher than those of healthy volunteers, while the HDL-cholesterol level (P = 0.0222) was significantly lower. Although the patients had very mild psychiatric symptoms and maintained functionally high levels, the glucose and lipid parameters were significantly impaired compared to healthy volunteers. A high level of plasma ghrelin might increase appetite, leading to exacerbation of metabolic impairment. SN - 1323-1316 UR - https://www.unboundmedicine.com/medline/citation/17239039/Glucose_and_lipid_metabolism_of_long_term_risperidone_monotherapy_in_patients_with_schizophrenia_ DB - PRIME DP - Unbound Medicine ER -